ReviewJournal of materials chemistry. B2024
Vaccine adjuvants: current status, research and development, licensing, and future opportunities.
Review in Journal of materials chemistry. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.Human vaccines & immunotherapeutics · 2026Review
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- A lymph node-targeted cell-nanoadjuvant conjugate enhances dendritic cell-T cell crosstalk for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection.PLoS neglected tropical diseases · 2026Article
- Polysaccharide Extracted from Longan (International journal of molecular sciences · 2026Article
- Synergistic Immunoenhancement of Recombinant PBP2a Vaccine Candidate by Biogenic Selenium Nanoparticles and MF59 Against Methicillin-Resistant Staphylococcus Aureus.Current microbiology · 2026Article
- Investigating the In Vitro Immunomodulatory Potential of Microparticulate β-L-Adenosine in Particulate Vaccine Candidates.Vaccines · 2026Article
- AS01Frontiers in immunology · 2026Article
- From Antibiotic Resistance to Bacterial Vaccines: A New Approach to Controlling Resistant Bacterial Infections.Infection and drug resistance · 2026Review
- Swine Group A rotavirus vaccines: current status, adjuvant strategies, challenges, and future perspectives.Frontiers in veterinary science · 2026Review
- Review
- Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects.Immunology · 2025Review
- Condensate nanovaccine adjuvants augment CD8Signal transduction and targeted therapy · 2025Article
- Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025Review
- Adjuvant screening of an inactivated Pasteurella multocida vaccine in mice and evaluation of its immunogenicity in sheep.Veterinary research communications · 2025Article
- Review
- Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.Molecular therapy. Nucleic acids · 2025Article
- Co-loaded simvastatin-ginsenoside Rh2 liposomes enhance cellular immune responses as vaccine adjuvants.Biochemistry and biophysics reports · 2025Article
- Natural vaccine adjuvants from traditional Chinese medicines: Mechanisms to applications.Acta pharmaceutica Sinica. B · 2025Review
- Comparison of Current Immunotherapy Approaches and Novel Anti-Cancer Vaccine Modalities for Clinical Application.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Vaccines represent one of the most significant inventions in human history and have revolutionized global health. Generally, a vaccine functions by triggering the innate immune response and stimulating antigen-presenting cells, leading to a defensive adaptive immune response against a specific pathogen's antigen. As a key element, adjuvants are chemical materials often employed as additives to increase a vaccine's efficacy and immunogenicity. For over 90 years, adjuvants have been essential components in many human vaccines, improving their efficacy by enhancing, modulating, and prolonging the immune response. Here, we provide a timely and comprehensive review of the historical development and the current status of adjuvants, covering their classification, mechanisms of action, and roles in different vaccines. Additionally, we perform systematic analysis of the current licensing processes and highlights notable examples from clinical trials involving vaccine adjuvants. Looking ahead, we anticipate future trends in the field, including the development of new adjuvant formulations, the creation of innovative adjuvants, and their integration into the broader scope of systems vaccinology and vaccine delivery. The article posits that a deeper understanding of biochemistry, materials science, and vaccine immunology is crucial for advancing vaccine technology. Such advancements are expected to lead to the future development of more effective vaccines, capable of combating emerging infectious diseases and enhancing public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.